PHARMACT HOLDING AG

D016.

A Biotechnology Platform for Distinct Development and Application Contexts.

Recombinant hyaluronidase technology with dual activity.
Built for pharmaceutical development and structured partnering.

EXPLORE D016 TECHNOLOGY → BELACT PROGRAM OVERVIEW →

STRUCTURE Recombinant protein platform with defined enzymatic characterization.

CONNECTION Technology, intellectual property, supply and application-specific development.

DEVELOPMENT BELACT is the lead pharmaceutical development program based on D016.

EVIDENCE Technical and preclinical evidence presented according to development stage.

Representational biotechnology visual · not a molecular structure of D016

◉

D016 TECHNOLOGY

Defined recombinant hyaluronidase technology and application-specific configurations.

→ ◇

BELACT PROGRAM

Lead pharmaceutical development program with HoFH as the initial development focus.

→ ▥

SCIENCE & EVIDENCE

Technical characterization, preclinical findings and development-stage evidence.

→ ∞

LICENSING & PARTNERING

Evaluation, supply, commercial licensing and strategic partnership structures.

→ ◎

ABOUT PHARMACT

Swiss biotechnology platform focused on D016 development, IP and partnering.

→

◇

RECOMBINANT PROTEINNon-animal derived

⌁

DUAL-ACTIVITY PLATFORMDefined enzymatic characterization

✓

PRECLINICAL EVIDENCEExploratory data generated

○

ORPHAN-FOCUSED DEVELOPMENTHoFH lead indication

↔

STRUCTURED PARTNERINGSupply, licensing and development

ONE CORE TECHNOLOGY

One Technology. Multiple Development Paths.

D016 recombinant hyaluronidase forms the basis for research, industrial, cosmetic and pharmaceutical development. Access is structured according to the intended field, development stage and applicable quality and regulatory context.

D016 TECHNOLOGY

Defined recombinant hyaluronidase technology with application-specific technical configurations.

EXPLORE →

INTELLECTUAL PROPERTY

Patent rights, published applications and proprietary know-how supporting controlled development and partnering.

EXPLORE →

LICENSING & PARTNERING

Evaluation, supply, commercial licensing and strategic partnership models defined by intended use.

EXPLORE →

BELACT

Lead pharmaceutical development program based on D016, with HoFH as the initial development focus.

EXPLORE →

D016 – THE CORE ASSET

A Defined Biotechnology Asset

D016 is Pharmact’s core biotechnology asset. Its development combines recombinant production, enzymatic characterization, analytical quality control, intellectual property and application-specific development.

BELACT is the lead pharmaceutical development program based on D016.

Explore the D016 technology →

SCIENCE IP D016 LICENSING BELACT

FROM TECHNOLOGY TO APPLICATION

Defined Configuration Before Application

D016 is not one undifferentiated product. Quality, documentation and regulatory requirements are defined according to intended use. Application-specific development is organized through dedicated programs, licensing structures and specialized partners.

D016 TECHNOLOGY

→

DEFINED CONFIGURATION

→

APPLICATION-SPECIFIC DEVELOPMENT

→

PROGRAM / PARTNER EXECUTION

LEAD PHARMACEUTICAL DEVELOPMENT

BELACT

BELACT is Pharmact’s lead pharmaceutical development program based on D016. The program evaluates D016 in defined therapeutic indications through preclinical, regulatory and planned clinical development, with HoFH as the initial development focus.

INVESTIGATIONAL STATUS

BELACT is not an approved medicinal product. Clinical safety and efficacy have not yet been established.

Explore BELACT development →

INTELLECTUAL PROPERTY

Technology Protected for Development and Partnering

Pharmact’s intellectual-property strategy supports controlled development, licensing and commercialization of D016 and defined application fields.

The scope of commercial rights depends on the relevant patent claims, jurisdiction, contractual rights and applicable third-party rights.

Explore Intellectual Property →

STRUCTURED ACCESS TO D016

Different Purposes Require Different Rights.

Access to D016 is structured according to intended use, development stage, quality requirements and required commercial rights.

EVALUATION & DEVELOPMENT

Defined research, feasibility and development access.

COMMERCIAL LICENSING

Contractually defined rights by field, application or territory.

STRATEGIC PARTNERSHIPS

Development, supply and rights structured around partner contribution.

D016 SUPPLY

Physical supply according to an agreed specification and intended use.

Supply ≠ License ≠ Ownership. Purchase or supply of D016 does not by itself grant broader intellectual-property, exclusivity or manufacturing-technology rights.

SEPARATE TOPICAL COSMETIC PATHWAY

RECELURA

Topical cosmetic formulation concepts based on D016 are developed separately through RECELURA. Cosmetic formulation, final-product safety, evidence and regulatory responsibilities remain independently defined from BELACT pharmaceutical development.

Visit RECELURA →

SCIENCE & EVIDENCE

Evidence Before Claims.

Pharmact separates established technical data, preclinical findings, development-stage evidence and questions requiring clinical evaluation.

ESTABLISHEDTechnical characterization

AVAILABLEPreclinical research

IN DEVELOPMENTPharmaceutical safety package

PLANNEDClinical development

NOT YET ESTABLISHEDClinical safety & efficacy

Explore Science & Evidence →

ABOUT PHARMACT

Focused Technology Development

Pharmact Holding AG develops, protects and commercializes biotechnology centered on D016. The company’s strategy combines technology development, intellectual property, pharmaceutical development, controlled supply and partner-based commercialization.

About Pharmact →

PARTNERING

Discuss D016 Development and Partnering

Pharmact engages with scientific, industrial, pharmaceutical, licensing and strategic partners interested in defined D016 development, supply or commercial opportunities.

DISCUSS A PARTNERSHIP CONTACT PHARMACT